| Patent Number |
Title Of Patent |
Date Issued |
| 5186938 |
Adhesive transdermal dosage layer |
February 16, 1993 |
| An adhesive bilayer transdermal dosage system capable of sustained release of a pharmaceutically active drug to the skin of a human patient having a first component layer which is a pharmaceutically active drug-containing essentially planar sheet of an at least partially cross-linked acr |
| 4983396 |
Percutaneous penetration enhancer of oleic acid and 2-ethyl-1,3-hexanediol |
January 8, 1991 |
| Pharmaceutical preparations comprised of a pharmaceutically active ingredient and a carrier which comprises a percutaneous penetration enhancer comprised of 2-ethyl-1, 3-hexanediol alone or in combination with oleic acid is disclosed. The 2-ethyl-1, 3-hexanediol may be present in an |
| 4885174 |
Percutaneous penetration enhancer of oleic acid and 2-ethyl-1,3-hexanediol |
December 5, 1989 |
| Pharmaceutical preparations comprised of a pharmaceutically active ingredient and a carrier which comprises a percutaneous penetration enhancer comprised of 2-ethyl-1, 3-hexanediol alone or in combination with oleic acid is disclosed. The 2-ethyl-1, 3-hexanediol may be present in an |
| 4863743 |
Controlled release potassium chloride |
September 5, 1989 |
| A controlled release potassium chloride tablet is disclosed which is comprised of potassium chloride crystals having a mesh size of about 30 to about 50 mesh which are coated with a coating material comprised of ethylcellulose and hydroxypropylcellulose. The coated crystals form micro |
| 4859707 |
Sulfur-substituted phenylacetamides |
August 22, 1989 |
| This invention relates to sulfur-substituted phenylacetamides of the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 may be the same or different and are H or CH.sub.3 ; R.sub.4 is SR.sub.5, ##STR2## R.sub.5 and R.sub.6 may be the same or different and are lower alkyl |
| 4764381 |
Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol |
August 16, 1988 |
| Pharmaceutical preparations comprised of a pharmaceutically active ingredient and a carrier which comprises a percutaneous penetration enhancer comprised of 2-ethyl-1, 3-hexanediol alone or in combination with oleic acid is disclosed. The 2-ethyl-1, 3-hexanediol may be present in an |
| 4722726 |
Method and apparatus for iontophoretic drug delivery |
February 2, 1988 |
| A device for iontophoretic delivery of active ingredient to a patient, that includes an electrode, a first cavity for holding a solution of at least partially active ingredient in ionizing form to be delivered to a patient, a member for maintaining a solution in the first cavity while al |
| 4708867 |
Minipellets |
November 24, 1987 |
| A minipellet dosage form of prednisone or prednisolone, resistant to attack by saliva but readily dissolvable in gastric juice, which comprises a mixture of prednisone or prednisolone and polyvinylpyrrolidone coated onto a nonpareil seed, and further coated with a layer of dimethylaminoe |
| 4689213 |
Method and composition for treating bronchospastic airway diseases |
August 25, 1987 |
| Bronchospastic diseases characterized by airway hyperreactivity are treated by administration of the calcium channel blocker gallopamil. Unlike other calcium channel blockers, the effective dose of gallopamil is small enough that undesirable side effects are not present. |
| 4679555 |
Method and apparatus for intrapulmonary delivery of heparin |
July 14, 1987 |
| An apparatus comprised of a canister having a valved opening thereon and containing, under pressure, heparin and a low boiling point propellant is disclosed. The valved opening can be activated to release a metered dose of aerosolized heparin to a patient or preferably to an inhalation d |
| 4639455 |
Means of aiding in the prevention of sudden infant death syndrome |
January 27, 1987 |
| A means of aiding in the prevention of Sudden Infant Death Syndrome (SIDS) is disclosed. The means comprises administering a pharmaceutically effective amount of the drug 6-methylene-6-desoxy-N-cylopryplymethyl-14-hydroxydihydronormorphone to an infant determined to be susceptible to |
| 4634587 |
Sustained release quinidine dosage form |
January 6, 1987 |
| A sustained release quindine dosage form is made from a plurality of pellets. Each pellet includes a quinidine-containing coating over a nonpareil seed, with a further coating of about 5 to about 15% by weight of a mixture of about 1.5 to about 9 parts by weight ethylcellulose to abo |
| 4594356 |
Method for inducing mydriasis in animals |
June 10, 1986 |
| A method of inducing short-term pupil diameter enlargement and reducing intraocular pressure in animals without significant systemic effects is disclosed. There is provided a site-specific chemical delivery method for topically applying to the eye of an animal, an effective ophthalmo |
| 4587118 |
Dry sustained release theophylline oral formulation |
May 6, 1986 |
| A dry sustained release oral dosage formulation of theophylline and a method of orally administering theophylline is disclosed. The oral formulation is comprised of a capsule which includes upper and lower parts which are connectible and easily separable from each other, and a plural |
| 4585452 |
Transdermal systemic dosage forms |
April 29, 1986 |
| Sustained release dosage forms that provide transdermal delivery of drugs utilizing the skin as the rate controlling membrane for the drugs. Methods for producing the dosage forms are also disclosed. The dosage forms are laminates produced by heating a laminate to a glass transition temp |
| 4579731 |
Polymeric diffusion burn matrix and method of use |
April 1, 1986 |
| A protective skin matrix is provided which is particularly suited for the protection of burned or wounded patients. The matrix may be either cured, applied in sheets, or painted or sprayed directly onto the burned or wounded patient. The protective skin matrix includes polyvinylpyrrolido |
| 4567185 |
Endorphin blockage |
January 28, 1986 |
| A method of permitting restful sleep at high altitudes is disclosed involving administration to a patient susceptible to Cheyne-Stokes respiration of a pharmaceutically acceptable amount of an endorphin-blocking compound capable of blocking the action of endogenous endorphins, whereb |
| 4562206 |
Orally effective inotropic compounds |
December 31, 1985 |
| A method for increasing cardiac contractility in a warm-blooded animal suffering from acutely depressed cardiac contractility which comprises administering to said animal an effective amount of a compound of the formula ##STR1## wherein R is hydrogen or isobutyrate, or a pharmace |
| 4556678 |
Sustained release propranolol tablet |
December 3, 1985 |
| A method of providing a patient suffering from cardiac arrhythmia with a sustained dosage of propranolol over a prolonged period of time comprises orally administering to the patient a tablet consisting essentially of a therapeutically effective amount of propranolol to provide a sustain |
| 4555399 |
Aspirin tablet |
November 26, 1985 |
| A tablet, which readily disintegrates in gastric fluid to give aspirin crystals coated with a polymeric film preventing the aspirin crystals from contacting the stomach wall but not preventing access of gastric fluid to the aspirin contained within the polymer film, which consists of a |
| 4542013 |
Trinitroglycerol sustained release vehicles and preparation therefrom |
September 17, 1985 |
| A trinitroglycerol-containing substantially disaccharide-free polymeric diffusion matrix is provided for the transdermal systemic delivery of trinitroglycerol through the skin of a patient. The polymeric diffusion matrix contains sufficient trinitroglycerol to be released over a prol |
| 4535157 |
Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone |
August 13, 1985 |
| An improved Wittig reaction for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone from naloxone and naltrexone utilizing an alkoxide base in an ethereal solvent. |
| 4511570 |
Senile dementia treatment |
April 16, 1985 |
| A method is provided for orally treating a patient suffering from senile dementia which comprises the periodic oral delivery of a pharmaceutically effective amount of 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphone to said patient, whereby the patient tends to r |
| 4508702 |
Sustained release aspirin |
April 2, 1985 |
| A sustained release aspirin dosage form permits the continuous delivery of aspirin into the gastrointestinal tract for a period of at least eight hours. The sustained release aspirin dosage form comprises a plurality of polymerically coated aspirin crystals each of which comprises an asp |
| 4496570 |
4,5.alpha.Epoxymorphinan -6-spiro-2'-(4'-carboxy,1',3'-thiazolidine)derivatives |
January 29, 1985 |
| Compounds the structural formula ##STR1## or their pharmaceutically acceptable salts, wherein X is H or CH.sub.3, Z is NH.sub.2 or OR.sub.6, R.sub.1 is a C.sub.1-8 alkyl, C.sub.3-6 -cycloalkylmethyl, or phenyl-C.sub.1-2 alkyl group,R.sub.2 is hydrogen, hydroxy, chloro or fluoro,R.sub |
| 4492685 |
Protective skin matrix |
January 8, 1985 |
| A protective skin matrix is provided which is particularly suited for the protection of burned or wounded patients. The matrix may be either cured, applied in sheets, or painted or sprayed directly onto the burned or wounded patient. The protective skin matrix includes polyvinylpyrrolido |
| 4484577 |
Drug delivery method and inhalation device therefor |
November 27, 1984 |
| A method and an apparatus for administering a drug through a breathing passage for absorption on the mucous tissue of a patient includes introducing an aerosol of the drug into an expanded bag and bidirectional channel for communicating the drug with the breathing passage of the pati |
| 4483860 |
Hyperkinetic child treatment agent |
November 20, 1984 |
| A method of orally treating a child having a tendency to be overactive to the extent of requiring an external control which comprises orally administering to said child a pharmaceutically effective amount of (-)-17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxymorpinan-6-one to s |
| 4483854 |
Systemic treatment of psoriasis using certain salicylates |
November 20, 1984 |
| Psoriasis is systemically treated by the administration of a salicylate which is capable of inhibiting the endogenous lipoxygenase present in psoriatic plaque fluid without the inhibition of the cyclooxygenase enzyme. |
| 4482533 |
Polymeric diffusion matrix containing propranolol |
November 13, 1984 |
| A self-supporting polymeric diffusion matrix provides for the sustained release of propranolol in order to deliver said propranolol to a patient. The matrix comprises from about 1 to about 60% by weight of a polar plasticizer, from about 5 to about 20% by weight polyvinylalcohol having a |
| 4472372 |
Polymeric diffusion matrix containing chlorpheniramine maleate |
September 18, 1984 |
| There is disclosed a polymeric diffusion matrix for the sustained release of chlorpheniramine maleate by transdermal delivery to a patient wherein the matrix comprises a polar plasticizer, polyvinylalcohol, polyvinylpyrrolidone, and a pharmaceutically effective amount of chlorphenira |
| 4470962 |
Polymeric diffusion matrix |
September 11, 1984 |
| A polymeric diffusion matrix is provided comprising from about 2 to about 60% glycerol, from about 2 to about 15% polyvinylalcohol, from about 2 to about 10% water soluble polymer with hydration sites which in combination with the remaining ingredients yields a matrix capable of sustaine |
| 4466953 |
Polymeric diffusion matrix |
August 21, 1984 |
| A polymeric diffusion matrix is provided comprising from about 2 to about 60% glycerol, from about 2 to about 15% polyvinylalcohol, from about 2 to about 10% water soluble polymer with hydration sites which in combination with the remaining ingredients yields a matrix capable of sustaine |
| 4460562 |
Polymeric diffusion matrix containing propranolol |
July 17, 1984 |
| A self-supporting polymeric diffusion matrix provides for the sustained release of propranolol in order to deliver the propranolol to a patient. The matrix comprises from about 1 to about 60% of a polar plasticizer, from about 6 to about 30% by weight polyvinylalcohol, from about 2 to |
| 4456587 |
Pheromone delivery system |
June 26, 1984 |
| This invention provides an aqueous mixture capable of being sprayed onto the leaves of plants and being cured in situ on the leaves. The thus cured mixture comprises polyvinylalcohol and polyvinylpyrrolidone. The cured mixture is capable of the sustained release of an active ingredient |
| 4454142 |
Hyperkinetic child treatment agent |
June 12, 1984 |
| Provided is a method of orally treating a child having a tendency to be overactive to the extent of requiring an external control which comprises orally administering to said child a pharmaceutically effective amount of 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphon |
| 4442941 |
Anti-spilling drug capsule |
April 17, 1984 |
| A capsule for housing pellets is disclosed having two members, the first with a raised portion and the second with a connecting groove and an annular groove for interconnection with the raised portion to secure the two members together. |
| 4438139 |
Polymeric diffusion matrix containing estrogens |
March 20, 1984 |
| A polymeric diffusion matrix for the sustained release, intravaginal administration of an estrogen is provided. The matrix consists of polyvinylalcohol, polyvinylpyrrolidone and a polar plasticizer. |
| 4432965 |
Quinidine sustained release dosage formulation |
February 21, 1984 |
| A sustained release oral dosage form is provided comprising a tablet core containing a pharmaceutically effective amount of quinidine. The tablet core is coated with a sustained release polymeric coating which contains about 5 to about 20 percent by weight polyethylene glycol component h |
| 4428926 |
Sustained release propranolol system |
January 31, 1984 |
| Propranolol is delivered orally in a sustained release dosage form. The dosage form is for oral administration and comprises a core containing the drug and a coating of an expandable lattice, said expandable lattice permitting the passage of water therethrough but which under conditions |
| 4428925 |
Sustained release glycerol trinitrate |
January 31, 1984 |
| Glycerol trinitrate is delivered orally in a sustained release dosage form. The dosage form is for oral administration and comprises a core containing the drug and a coating of an expandable lattice, said expandable lattice permitting the passage of water therethrough but which under con |
| 4425336 |
3,4-Dih ydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin c |
January 10, 1984 |
| Cardiac contractility agents are provided which are 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamin e cyclodextrin complexes. |
| 4424209 |
3,4-Di -isobutyryloxy-N-[3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl]-beta-phene thylamine cyc |
January 3, 1984 |
| Cardiac contractility agents are provided which are 3,4-di-isobutyryloxy-N-[3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl]-beta- phenethylamine, preferably orally deliverable forms which are cyclodextrin complexes. |
| 4321252 |
Polymeric diffusion matrix containing ester derivatives of estradiol |
March 23, 1982 |
| There is disclosed a polymeric diffusion matrix for the sustained release of an estradiol ester by delivery to a patient requiring uterine wall maintenance or other types of estrogen therapy wherein the matrix comprises a polar plasticizer, polyvinylalcohol, polyvinylpyrrolidone, and |
| 4297995 |
Bandage containing attachment post |
November 3, 1981 |
| A bandage is disclosed comprising a lower portion and a matrix. The lower portion has an upper surface, a base plate on the upper surface, and a post extending from the surface of the base plate. The matrix is attached to the lower portion by means of a hole extending through the matrix |
| 4294820 |
Polymeric diffusion matrix containing phenylephrine |
October 13, 1981 |
| There is disclosed a polymeric diffusion matrix for the sustained release of phenylephrine by transdermal delivery to a patient wherein the matrix comprises a polar plasticizer, polyvinylalcohol, polyvinylpyrrolidone, and a pharmaceutically effective amount of phenylephrine. |
| 4292303 |
Polymeric diffusion matrix containing clonidine |
September 29, 1981 |
| There is disclosed a polymeric diffusion matrix for the sustained release of clonidine by transdermal delivery to a patient wherein the matrix comprises a polar plasticizer, polyvinylalcohol, polyvinylpyrrolidone, and a pharmaceutically effective amount of clonidine. |
| 4292302 |
Polymeric diffusion matrix containing terbutaline |
September 29, 1981 |
| There is disclosed a polymeric diffusion matrix for the sustained release of terbutaline by transdermal delivery to a patient wherein the matrix comprises a polar plasticizer, polyvinylalcohol, polyvinylpyrrolidone, and a pharmaceutically effective amount of terbutaline. |
| 4292301 |
Polymeric diffusion matrix containing ephedrine |
September 29, 1981 |
| There is disclosed a polymeric diffusion matrix for the sustained release of ephedrine by transdermal delivery to a patient wherein the matrix comprises a polar plasticizer, polyvinylalcohol, polyvinylpyrrolidone, and a pharamaceutically effective amount of ephedrine. |
| 4291015 |
Polymeric diffusion matrix containing a vasodilator |
September 22, 1981 |
| A polymeric diffusion matrix containing a vasodilator is provided comprising from about 2 to about 60% of a polar plasticizer, e.g., glycerol, from about 2 to about 15% of a matrix component, e.g., polyvinylalcohol, from about 2 to about 10% of a water-soluble polymer with hydration |
